Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-27 23:03:18 - browse：555

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Medicare has officially expanded its coverage policy for brain scans that detect a brain plaque associated with Alzheimer’s disease, the agency announced on Friday.

Amyloid PET scans are important tools to help determine whether patients with mild cognitive impairment are good candidates for new Alzheimer’s drugs, including Eisai and Biogen’s drug Leqembi, which means there will likely be an increase in demand for the scans as uptake increases.

Previously, Medicare limited coverage for the drug to patients enrolled in clinical studies, and only covered one scan in a patient’s lifetime. The new coverage policy removes those restrictions and delegates decisions about how many scans to cover to regional Medicare administrators.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： What will Novo Nordisk's VC do with its influx of cash?

WSS

Will an HIV vaccine ever be a reality?

Long Covid research funding gets a major boost from NIH

Why Eli Lilly’s earnings didn’t quite live up to the hype

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Experts study whether long Covid risk adds up with each reinfection

Congress might make insulin pumps more accessible to the blind

explore

Wikipedia

focus

Apple is now the first public company to be valued at $3 trillion

Long Covid research funding gets a major boost from NIH

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Flu, Covid vaccination rates decline, new survey data show

New air purifier tech could be key to improving indoor air quality

Some top drug companies are starting to take action on climate

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

How to save PrEP access — and even expand it

Why Eli Lilly’s earnings didn’t quite live up to the hype

focus

Tome Biosciences co

The United States is paying nearly triple for new Covid vaccines

Why don't Americans have at

Health insurers' Q3 question: how much care are people getting?

Websites selling Wegovy, Zepbound ingredients targeted by FDA

European officials brace for rough respiratory virus season

knowledge

entertainment

hotspot

hotspot